Hormone receptors in gynecological cancers: focus on androgen receptor status
DOI:
https://doi.org/10.18203/2320-1770.ijrcog20253741Keywords:
Gynecological cancers, Hormone receptors, Androgen receptor, Estrogen receptor, Progesterone receptor, p53, Endocrine therapyAbstract
Background: Hormonal therapy and chemotherapy remain the primary treatment modalities for advanced and recurrent gynecologic malignancies. The presence or absence of hormone receptors has significant prognostic value in gynecological cancers. Previous studies have shown that high estrogen receptor (ER) and progesterone receptor (PR) levels in endometrial cancer predict favorable survival, while loss of PR expression in ovarian cancers correlates with recurrence. However, the role of androgen receptors (AR) in these cancers is not fully understood.
Methods: This observational study analyzed the immunohistochemical expression of AR, ER alpha (ERα), PR, and p53 in patients diagnosed with gynecologic cancers at a tertiary care center. Hormonal receptor expression was evaluated and correlated with tumor type and histopathological features.
Results: Prominent expression of ARs was observed across all categories of gynecological cancers included in the study. The expression profiles of ER, PR, and p53 varied among tumor subtypes, reflecting their potential prognostic and therapeutic significance.
Conclusions: Androgens appear to play a role in the pathogenesis of gynecological cancers. Hormonal expression profiling may guide future endocrine therapy strategies and could be considered as a potential salvage treatment option similar to that used in ovarian cancers. These findings underscore the importance of detecting hormone receptor expression in all gynecological malignancies.
Metrics
References
Zhang Y, Wang R, Feng Y, Ma F. The role of sialyltransferases in gynecological malignant tumors. Life Sci. 2020;263:118670. DOI: https://doi.org/10.1016/j.lfs.2020.118670
Ajithkumar TV, Minimole AL, John MM, Ashokkumar OS. Primary Fallopian Tube Carcinoma. Obstet Gynecol Survey. 2005;60(4):247-52. DOI: https://doi.org/10.1097/01.ogx.0000158506.23663.79
Stasenko M, Fillipova O, Tew WP. Fallopian Tube Carcinoma. J Oncol Pract. 2019;15(7):375-82. DOI: https://doi.org/10.1200/JOP.18.00662
Zhu B, Gu H, Mao Z, Beeraka NM, Zhao X, Anand MP, et al. Global burden of gynaecological cancers in 2022 and projections to 2050. J Global Health. 2024;14:04155. DOI: https://doi.org/10.7189/jogh.14.04155
Shen Z, Luo H, Li S, Sheng B, Zhao M, Zhu H, et al. Correlation between estrogen receptor expression and prognosis in epithelial ovarian cancer: a meta-analysis. Oncotarget. 2017;8(37):62400-13. DOI: https://doi.org/10.18632/oncotarget.18253
Luo H, Li S, Zhao M, Sheng B, Zhu H, Zhu X. Prognostic value of progesterone receptor expression in ovarian cancer: a meta-analysis. Oncotarget. 2017;8(22):36845-56. DOI: https://doi.org/10.18632/oncotarget.15982
Mittica G, Senetta R, Scotto G, Aglietta M, Maggiorotto F, Ghisoni E, et al. Androgen receptor status predicts development of brain metastases in ovarian cancers. Oncotarget. 2017;8(25):41143-53. DOI: https://doi.org/10.18632/oncotarget.17068
Mittica G, Goia M, Gambino A, Scotto G, Fonte M, Senetta R, et al. Validation of Androgen Receptor loss as a risk factor for the development of brain metastases from ovarian cancers. J Ovarian Res. 2020;13(1):53. DOI: https://doi.org/10.1186/s13048-020-00655-2
Borella F, Bertero L, Morrone A, Gambella A, Bovetti M, Cosma S, et al. Brain Metastases from Ovarian Cancer: Current Evidence in Diagnosis, Treatment, and Prognosis. Cancers. 2020;12(8):2156. DOI: https://doi.org/10.3390/cancers12082156
Maček P, Molinari N, Sobočan M, Knez J. What Role do Androgens Play in Endometrial Cancer? J Personalized Med. 2023;13(2):341. DOI: https://doi.org/10.3390/jpm13020341
Munoz J, Wheler JJ, Kurzrock R. Androgen receptors beyond prostate cancer: an old marker as a new target. Oncotarget. 2015;6(2):592-603. DOI: https://doi.org/10.18632/oncotarget.2831
McCluggage WG, Singh N, Gilks CB. Key changes to the World Health Organization (WHO) classification of female genital tumours introduced in the 5th edition (2020). Histopathology. 2022;80(5):762-78. DOI: https://doi.org/10.1111/his.14609
Ibeanu OA. Molecular pathogenesis of cervical cancer. Cancer Biol Therapy. 2011;11(3):295-306. DOI: https://doi.org/10.4161/cbt.11.3.14686
Li Y, Khandia R, Papadakis M, Alexiou A, Simonov AN, Khan AA. An investigation of codon usage pattern analysis in pancreatitis associated genes. BMC Genomic Data. 2022;23(1):81. DOI: https://doi.org/10.1186/s12863-022-01089-z
Kumar U, Khandia R, Singhal S, Puranik N, Tripathi M, Pateriya AK, et al. Insight into Codon Utilization Pattern of Tumor Suppressor Gene EPB41L3 from Different Mammalian Species Indicates Dominant Role of Selection Force. Cancers. 2021;13(11):2739. DOI: https://doi.org/10.3390/cancers13112739
Austin RM, Zhao C. Type 1 and type 2 cervical carcinomas: some cervical cancers are more difficult to prevent with screening. Cytopathology. 2012;23(1):6-12. DOI: https://doi.org/10.1111/j.1365-2303.2011.00955.x
Bulk S, Visser O, Rozendaal L, Verheijen RHM, Meijer CJLM. Cervical cancer in the Netherlands 1989-1998: Decrease of squamous cell carcinoma in older women, increase of adenocarcinoma in younger women. Int J Cancer. 2005;113(6):1005-9. DOI: https://doi.org/10.1002/ijc.20678
Schneider A, Hotz M, Gissmann L. Increased prevalence of human papillomaviruses in the lower genital tract of pregnant women. Int J Cancer. 1987;40(2):198-201. DOI: https://doi.org/10.1002/ijc.2910400212
Monsonego J, Magdelenat H, Catalan F, Coscas Y, Zerat L, Sastre X. Estrogen and progesterone receptors in cervical human papillomavirus related lesions. Int J Cancer. 1991;48(4):533-9. DOI: https://doi.org/10.1002/ijc.2910480410
Bigler LR, Thigpen JT, Blessing JA, Fiorica J, Monk BJ. Evaluation of tamoxifen in persistent or recurrent nonsquamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Int J Gynecolog Cancer. 2004;14(5):871-4. DOI: https://doi.org/10.1136/ijgc-00009577-200409000-00020
Zhang Y, Zhao D, Gong C, Zhang F, He J, Zhang W, et al. Prognostic role of hormone receptors in endometrial cancer: a systematic review and meta-analysis. World J Surg Oncol. 2015;13(1):208. DOI: https://doi.org/10.1186/s12957-015-0619-1
Ethier JL, Desautels DN, Amir E, MacKay H. Is hormonal therapy effective in advanced endometrial cancer? A systematic review and meta-analysis. Gynecologic Oncol. 2017;147(1):158-66. DOI: https://doi.org/10.1016/j.ygyno.2017.07.002
Tangen IL, Werner HMJ, Berg A, Halle MK, Kusonmano K, Trovik J, et al. Loss of progesterone receptor links to high proliferation and increases from primary to metastatic endometrial cancer lesions. Europ J Cancer. 2014;50(17):3003-10. DOI: https://doi.org/10.1016/j.ejca.2014.09.003
Koivisto-Korander R, Butzow R, Koivisto AM, Leminen A. Immunohistochemical studies on uterine carcinosarcoma, leiomyosarcoma, and endometrial stromal sarcoma: expression and prognostic importance of ten different markers. Tumor Biol. 2011;32(3):451-9. DOI: https://doi.org/10.1007/s13277-010-0138-1
Leitao MM, Hensley ML, Barakat RR, Aghajanian C, Gardner GJ, Jewell EL, et al. Immunohistochemical expression of estrogen and progesterone receptors and outcomes in patients with newly diagnosed uterine leiomyosarcoma. Gynecol Oncol. 2012;124(3):558-62. DOI: https://doi.org/10.1016/j.ygyno.2011.11.009
Tangen IL, Onyango TB, Kopperud R, Berg A, Halle MK, Øyan AM, et al. Androgen receptor as potential therapeutic target in metastatic endometrial cancer. Oncotarget. 2016;7(31):49289-98. DOI: https://doi.org/10.18632/oncotarget.10334
Slaughter DP, Southwick HW, Smejkal W. “Field cancerization” in oral stratified squamous epithelium. Clinical implications of multicentric origin. Cancer. 1953;6(5):963-8. DOI: https://doi.org/10.1002/1097-0142(195309)6:5<963::AID-CNCR2820060515>3.0.CO;2-Q
Koyamatsu Y, Yokoyama M, Nakao Y, Fukuda K, Saito T, Matsukuma K, et al. A comparative analysis of human papillomavirus types 16 and 18 and expression of p53 gene and Ki-67 in cervical, vaginal, and vulvar carcinomas. Gynecolog Oncol. 2003;90(3):547-51. DOI: https://doi.org/10.1016/S0090-8258(03)00401-3
Robboy SJ, Young RH, Welch WR, Truslow GY, Prat J, Herbst AL, et al. Atypical vaginal adenosis and cervical ectropion. Association with clear cell adenocarcinoma in diethylstilbestrol-exposed offspring. Cancer. 1984;54(5):869-75. DOI: https://doi.org/10.1002/1097-0142(19840901)54:5<869::AID-CNCR2820540519>3.0.CO;2-I
Deli T, Orosz M, Jakab A. Hormone Replacement Therapy in Cancer Survivors-Review of the Literature. Pathol Oncol Res. 2020;26(1):63-78. DOI: https://doi.org/10.1007/s12253-018-00569-x
Bancher-Todesca D, Obermair A, Bilgi S, Kohlberger P, Kainz C, Breitenecker G, et al. Angiogenesis in Vulvar Intraepithelial Neoplasia. Gynecologic Oncolo. 1997;64(3):496-500. DOI: https://doi.org/10.1006/gyno.1996.4582
Sherman KJ, Daling JR, McKnight B, Chu J. Hormonal factors in vulvar cancer. A case-control study. J Reproduct Med. 1994;39(11):857-61.
Mirkin S, Pinkerton JV, Kagan R, Thompson JR, Pan K, Pickar JH, et al. Gynecologic Safety of Conjugated Estrogens Plus Bazedoxifene: Pooled Analysis of Five Phase 3 Trials. J Women’s Health. 2016;25(5):431-42. DOI: https://doi.org/10.1089/jwh.2015.5351
Elattar A, Warburton KG, Mukhopadhyay A, Freer RM, Shaheen F, Cross P, et al. Androgen receptor expression is a biological marker for androgen sensitivity in high grade serous epithelial ovarian cancer. Gynecologic Oncol. 2012;124(1):142-7. DOI: https://doi.org/10.1016/j.ygyno.2011.09.004
Akahira J, Suzuki T, Ito K, Darnel RD, Moriya T, Sato S, et al. Expression of 5α‐Reductases in Human Epithelial Ovarian Cancer: Its Correlation with Androgen Receptor Status. Jap J Cancer Res. 2001;92(9):926-32. DOI: https://doi.org/10.1111/j.1349-7006.2001.tb01182.x
Feng Z, Wen H, Ju X, Bi R, Chen X, Yang W, et al. Hormone receptor expression profiles differ between primary and recurrent high-grade serous ovarian cancers. Oncotarget. 2017;8(20):32848-55. DOI: https://doi.org/10.18632/oncotarget.15858
Feng Z, Wen H, Bi R, Ju X, Chen X, Yang W, et al. A clinically applicable molecular classification for high-grade serous ovarian cancer based on hormone receptor expression. Scientific Rep. 2016;6(1):25408. DOI: https://doi.org/10.1038/srep25408
van Kruchten M, van der Marel P, de Munck L, Hollema H, Arts H, Timmer-Bosscha H, et al. Hormone receptors as a marker of poor survival in epithelial ovarian cancer. Gynecologic Oncol. 2015;138(3):634-9. DOI: https://doi.org/10.1016/j.ygyno.2015.06.032
Park BY, Grisham RN, den Hollander B, Thapi D, Berman T, de Stanchina E, et al. Tumor Inhibition by Enzalutamide in a Xenograft Model of Ovarian Cancer. Cancer Investigation. 2016;34(10):517-20. DOI: https://doi.org/10.1080/07357907.2016.1242598
Buttarelli M, Mascilini F, Zannoni GF, Ciucci A, Martinelli E, Filippetti F, et al. Hormone receptor expression profile of low-grade serous ovarian cancers. Gynecologic Oncol. 2017;145(2):352-60. DOI: https://doi.org/10.1016/j.ygyno.2017.02.029
Zhu H, Zhu X, Zheng L, Hu X, Sun L, Zhu X. The role of the androgen receptor in ovarian cancer carcinogenesis and its clinical implications. Oncotarget. 2017;8(17):29395-405. DOI: https://doi.org/10.18632/oncotarget.12561
Downloads
Published
How to Cite
Issue
Section
